Four of seventeen evaluable patients had SD for 12 weeks to 14 months, and 3 had their residual tumor removed with no further treatment and remained in remission at 6, 12, and 16 months, albeit no post-infusion expansion of anti-HER2 CAR-T cells in the PB was observed in most of the treated patients. Here, ERBB2 is linked to neoplasm.